Tag: Competition

Displaying 21 - 40 of 2499 results.

Pages

From: Gillis, Diana L.Sent: Friday, December 09, 2016 3:02 PMTo: [REDACTED]Cc: [REDACTED]Subject: RE: HSR earnout related guidance Early termination may be granted at any time during the waiting period. From: [REDACTED]Sent: Friday, December 09, 2016 2:59 PMTo: Gillis, Diana L.Cc: [...
[REDACTED] Acquiring C would be separately reportable. Do not allocate C’s assets to A and B. Regards Evan From: [REDACTED]Sent: Monday, December 05, 2016 4:13 PMTo: Storm, EvanCc: [REDACTED]Subject: RE: Request for Informal Advice Evan, We’ve tracked down the relevant information in...
From: Carson, TimothySent: Monday, December 05, 2016 4:32 PMTo: [REDACTED]Cc: [REDACTED]; Walsh, Kathryn E.; Berg, Karen E.; Gillis, Diana L.; Whitehead, Nora; Storm, Evan; Shaffer, KristinSubject: RE: Question Regarding Reporting Structure [REDACTED]
President Donald J. Trump has designated Maureen K. Ohlhausen as Acting Chairman of the Federal Trade Commission by a White House order.
The Federal Trade Commission has refiled a complaint and filed a proposed stipulated order in federal court to resolve charges that Endo Pharmaceuticals Inc.
With some exceptions, Section 8 of the Clayton Act prohibits the same individual from serving as an officer or director of two competing corporations. Like other portions of the forward-looking Clayton Act (including Section 7 with its proscription on mergers that are likely to harm...
For 2017, the size-of-transaction threshold for reporting proposed mergers and acquisitions under Section 7A of the Clayton Act will increase from $78.2 million to $80.8 million. The new 2017 thresholds under Section 8 of the Act that trigger prohibitions on certain interlocking memberships on...
OFTACOOP, a Puerto Rico ophthalmologist cooperative, has agreed to settle Federal Trade Commission charges that its actions harmed competition. The complaint charges that  OFTACOOP – also known as Cooperativa de Médico Oftalmólogos de Puerto Rico –  unlawfully orchestrated an agreement among...
Mallinckrodt ARD Inc., formerly known as Questcor Pharmaceuticals, Inc., and its parent company, Mallinckrodt plc, have agreed to pay $100 million to settle Federal Trade Commission charges that they violated the antitrust laws when Questcor acquired the rights to a drug that threatened its...
Mallinckrodt ARD Inc., formerly known as Questcor Pharmaceuticals, Inc., and its parent company, Mallinckrodt plc, agreed to pay $100 million to settle charges that they violated the antitrust laws when Questcor acquired the rights to a drug that threatened its monopoly in the U.S....

Pages